191 related articles for article (PubMed ID: 37185400)
21. Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: A retrospective case-control study.
Liu J; Duan S; Wang C; Wang Y; Peng H; Niu Z; Yao S
Front Endocrinol (Lausanne); 2022; 13():1035418. PubMed ID: 36531447
[TBL] [Abstract][Full Text] [Related]
22. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population.
Cai J; Lin C; Lai S; Liu Y; Liang M; Qin Y; Liang X; Tan A; Gao Y; Lu Z; Wu C; Huang S; Yang X; Zhang H; Kuang J; Mo Z
Lipids Health Dis; 2021 Oct; 20(1):145. PubMed ID: 34706716
[TBL] [Abstract][Full Text] [Related]
23. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
24. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation.
Ye J; Zhuang X; Li X; Gong X; Sun Y; Wang W; Feng S; Wu T; Zhong B
Metabolism; 2022 Nov; 136():155294. PubMed ID: 35995280
[TBL] [Abstract][Full Text] [Related]
25. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
26. The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer.
Wei S; Hao Y; Dong X; Huang J; Huang K; Xie Y; Liu H; Wei C; Xu J; Huang W; Dong L; Yang J
Front Endocrinol (Lausanne); 2023; 14():985858. PubMed ID: 36891047
[TBL] [Abstract][Full Text] [Related]
27. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
28. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
[TBL] [Abstract][Full Text] [Related]
29. Hyperuricemia as an independent risk factor for metabolic dysfunction-associated fatty liver disease in nonobese patients without type 2 diabetes mellitus.
Liu J; Wang C; Wang YT; Liu JX; Zhou TH; Yao SK; Chen G
Am J Physiol Endocrinol Metab; 2023 Jul; 325(1):E62-E71. PubMed ID: 37285598
[TBL] [Abstract][Full Text] [Related]
30. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
31. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
32. An Observational and Cross-Sectional Study of the Prevalence of Breast Lesions and Metabolic Dysfunction-Associated Fatty Liver Disease and their Relationship in China.
Li S; Xu Z; Li H; Tang J; Liang XY; Tian S; Wu J; Li X; Liu ZL; Xiao J; Chen YL; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
J Gastrointestin Liver Dis; 2022 Mar; 31(1):31-39. PubMed ID: 35306559
[TBL] [Abstract][Full Text] [Related]
33. Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study.
Ma YL; Ke JF; Wang JW; Wang YJ; Xu MR; Li LX
Front Endocrinol (Lausanne); 2023; 14():1133991. PubMed ID: 37223022
[TBL] [Abstract][Full Text] [Related]
34. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
[TBL] [Abstract][Full Text] [Related]
35. J-Shaped Relationship Between Serum Prolactin and Metabolic-Associated Fatty Liver Disease in Female Patients With Type 2 Diabetes.
Zhu C; Ma H; Huang D; Li G; Gao J; Cai M; You H; Bu L; Qu S
Front Endocrinol (Lausanne); 2022; 13():815995. PubMed ID: 35222274
[TBL] [Abstract][Full Text] [Related]
36. [Associations between serum GDF15 and glycolipid metabolism disorder in metabolic associated fatty liver patients].
Li X; Yu XM; Li EH; Chen PH; Zheng LM; Zhang S
Zhonghua Nei Ke Za Zhi; 2023 Aug; 62(8):987-992. PubMed ID: 37528037
[No Abstract] [Full Text] [Related]
37. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG
Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138
[TBL] [Abstract][Full Text] [Related]
38. Metabolic-associated fatty liver disease increases the risk of end-stage renal disease in patients with biopsy-confirmed diabetic nephropathy: a propensity-matched cohort study.
Zou Y; Zhao L; Zhang J; Wang Y; Wu Y; Ren H; Wang T; Zhao Y; Xu H; Li L; Tong N; Liu F
Acta Diabetol; 2023 Feb; 60(2):225-233. PubMed ID: 36319797
[TBL] [Abstract][Full Text] [Related]
39. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease.
Yang C; He Q; Chen Z; Qin JJ; Lei F; Liu YM; Liu W; Chen MM; Sun T; Zhu Q; Wu Y; Zhuo M; Cai J; Mao W; Li H
Front Endocrinol (Lausanne); 2022; 13():821689. PubMed ID: 35250880
[TBL] [Abstract][Full Text] [Related]
40. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes.
Samimi S; Rajabzadeh S; Rabizadeh S; Nakhjavani M; Nakhaei P; Avanaki FA; Esteghamati A
Eur J Med Res; 2022 Jul; 27(1):112. PubMed ID: 35818084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
